Corbus Pharmaceuticals: Q3 Earnings Insights

Shares of Corbus Pharmaceuticals CRBP decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 34.37% year over year to ($0.43), which missed the estimate of ($0.42).

Revenue of $1,231,000 decreased by 52.47% from the same period last year, which missed the estimate of $2,310,000.

Outlook

Corbus Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/crbp/mediaframe/41687/indexl.html

Technicals

Company's 52-week high was at $9.78

52-week low: $0.91

Price action over last quarter: down 81.85%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.